Multiple Myeloma

CancerNetwork® sat down with Larry Anderson, MD, PhD, at the 18th International Myeloma Workshop to talk about how the emergence of CAR T-cell therapies in multiple myeloma affects multidisciplinary clinicians.

Different markers and tests that are used to monitor disease status and treatment response in patients with multiple myeloma.

Findings from a phase 1/2 study indicated that patients with relapsed/refractory multiple myeloma who were treated with iberdomide plus dexamethasone and daratumumab/bortezomib or carfilzombib experienced promising efficacy and tolerable safety.

Patients with multiple myeloma with standard or high-risk cytogenic abnormalities who were treated with carfilzomib, lenalidomide, and dexamethasone plus autologous stem cell transplant experienced promising responses.

Updated results confirmed the safety and efficacy of the quadruplet regimen of fixed-dose isatuximab-irfcc in combination with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma with no immediate intent for transplant.

The combination of daratumumab plus lenalidomide and dexamethasone demonstrated a significant overall survival benefit compared with lenalidomide and dexamethasone alone for patients with newly diagnosed multiple myeloma.

Kicking off a discussion regarding treatment approaches for transplant-ineligible multiple myeloma, a panel of hematologist-oncologists highlights goals of therapy for newly diagnosed patients.

Patients taking teclistamab for relapsed or refractory multiple myeloma saw durable response, and a well-tolerated toxicity profile.

Patients with relapsed or refractory multiple myeloma with or without t(11;14) experienced promising responses after being treated with venetoclax plus daratumumab and dexamethasone, as well as venetoclax plus daratumumab, dexamethasone, and bortezomib.

Researchers utilized a ctDNA assay to evaluate minimal residual disease in patients with multiple myeloma post-autologous stem cell transplantation.

The FDA granted a fast track designation for ALLO-605 based on its potential to treat patients with relapsed/refractory multiple myeloma who progressed on previous standard multiple myeloma therapies.

Early phase data indicate that elranatamab may be a safe and efficacious treatment for patients with relapsed/refractory multiple myeloma

Based on detrimental effects on overall survival, the FDA has issued a safety warning for melphalan flufenamide in relapsed multiple myeloma.

Moreau discussed conclusions drawn from part 2 of the CASSIOPEIA trial and the need for further follow-up with bortezomib, thalidomide and dexamethasone plus maintenance daratumumab in newly diagnosed multiple myeloma.

At EHA 2021, Shaji Kumar, MD, reviews the toxicity profile of daratumumab plus lenalidomide and dexamethasone for patients with transplant-ineligible multiple myeloma in the first-line setting.

The FDA approved the combination of daratumumab and hyaluronidase-fihj plus pomalidomide/dexamethasone as therapy for certain patients with pretreated multiple myeloma.

At ASCO 2021, Shaji Kumar, MD, talked about the impact of adding daratumumab maintenance to therapy for patients with newly diagnosed multiple myeloma in the CASSIOPEIA trial.

During a discussion at ASCO 2021, Mounzer Agha, MD, talked about mitigation strategies used by the investigators from the CARTITUDE-2 trial to prevent cognitive and neuro-movement disorders commonly associated with CAR T-cell therapy.

The FDA has requested a partial clinical hold on all trials featuring melflufen following the updated results of the phase 3 OCEAN study in relapsed/refractory multiple myeloma.

Moreau detailed the patient characteristics of those enrolled on the CASSIOPEIA trial, which investigating bortezomib, thalidomide and dexamethasone plus daratumumab in patients with newly diagnosed multiple myeloma.

At EHA 2021, Shaji Kumar, MD, reflects on the significance of 5-year data from the MAIA study of a daratumumab combination in patients with multiple myeloma.

Agha emphasized that the annual conference allows investigators to set the foundation for what’s to come in the treatment of multiple myeloma and other hematologic malignancies.

Final overall survival results from TOURMALINE-MM1 failed to show statistical significance of an ixazomib combination for relapsed/refractory multiple myeloma overall.

Usmani detailed the primary results from CARTITUDE-1, focusing on overall response rate and stringent complete responses.

Moreau discussed the implications of the second part of the CASSIOPEIA trial at the 2021 ASCO Annual Meeting.

At EHA 2021, Shaji Kumar, MD, reflects on the significance of 5-year data from the MAIA study of daratumumab plus lenalidomide/dexamethasone in patients with newly diagnosed multiple myeloma.

Ixazomib plus daratumumab and low-dose dexamethasone yielded a high response rate and improved quality of life in frail patients with newly diagnosed multiple myeloma.

Moreau highlighted important updates in the field of multiple myeloma, including the CARTITUDE-1 trial, which yielded promising results with ciltacabtagene autoleucel and read out at the 2021 ASCO Annual Meeting.

Shaji Kumar, MD, talks about 5-year follow-up data regarding the use of daratumumab, lenalidomide, and dexamethasone in patients with multiple myeloma who are not eligible for transplant.

Usmani highlighted the FORTE study as one of the trials investigating the high-risk cohort of patients.